Table 5 Timing of Tocilizumab administration after intubation in MVP.

From: Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients

Timing of Tocilizumab administration

All (n = 126)

Survival

N (%)

Mortality

N (%)

P value

Administration within 24 h of intubation

41

26(63.4)

15(36.6)

< 0.001***

Administration after 24 h of intubation

85

28(32.9)

57 (67.1)

 

Tocilizumab administration after 24 h from intubation

OR 3.53 (CI 1.64–7.85)

  1. ***highly Significant, if p-value < 0.001.
Back to article page